IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 228 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $100,752,789 | -29.8% | 22,143,470 | +8.6% | 0.00% | -33.3% |
| Q2 2023 | $143,583,532 | +73.6% | 20,395,388 | +50.6% | 0.00% | +50.0% |
| Q1 2023 | $82,730,189 | -10.5% | 13,540,129 | -6.4% | 0.00% | -33.3% |
| Q4 2022 | $92,419,094 | -32.3% | 14,463,082 | +1.5% | 0.00% | -25.0% |
| Q3 2022 | $136,551,000 | -7.4% | 14,253,754 | +6.7% | 0.00% | 0.0% |
| Q2 2022 | $147,529,000 | -28.2% | 13,363,027 | +8.3% | 0.00% | -20.0% |
| Q1 2022 | $205,489,000 | -11.8% | 12,341,653 | +1.2% | 0.01% | 0.0% |
| Q4 2021 | $232,856,000 | -20.8% | 12,197,787 | +2.3% | 0.01% | -28.6% |
| Q3 2021 | $294,169,000 | -7.6% | 11,928,989 | -2.5% | 0.01% | -12.5% |
| Q2 2021 | $318,392,000 | -16.6% | 12,236,411 | +1.5% | 0.01% | -20.0% |
| Q1 2021 | $381,614,000 | -30.7% | 12,053,487 | +1.6% | 0.01% | -37.5% |
| Q4 2020 | $550,555,000 | +42.0% | 11,865,382 | +0.7% | 0.02% | +23.1% |
| Q3 2020 | $387,750,000 | +15.5% | 11,778,527 | -3.7% | 0.01% | +8.3% |
| Q2 2020 | $335,670,000 | +0.8% | 12,228,470 | +9.9% | 0.01% | -14.3% |
| Q1 2020 | $333,153,000 | +10.9% | 11,129,211 | +2.5% | 0.01% | +40.0% |
| Q4 2019 | $300,415,000 | +56.8% | 10,853,129 | +3.1% | 0.01% | +42.9% |
| Q3 2019 | $191,613,000 | -8.0% | 10,528,180 | +24.0% | 0.01% | -12.5% |
| Q2 2019 | $208,220,000 | +277.3% | 8,491,841 | +46.3% | 0.01% | +300.0% |
| Q1 2019 | $55,185,000 | +7.9% | 5,802,878 | +0.4% | 0.00% | 0.0% |
| Q4 2018 | $51,145,000 | +12.3% | 5,779,069 | +42.7% | 0.00% | 0.0% |
| Q3 2018 | $45,550,000 | -5.0% | 4,048,782 | +8.1% | 0.00% | 0.0% |
| Q2 2018 | $47,950,000 | -13.4% | 3,746,133 | +14.4% | 0.00% | 0.0% |
| Q1 2018 | $55,362,000 | +151.4% | 3,275,856 | +19.0% | 0.00% | +100.0% |
| Q4 2017 | $22,018,000 | +13.3% | 2,752,223 | +9.8% | 0.00% | 0.0% |
| Q3 2017 | $19,428,000 | +20.6% | 2,506,839 | +14.4% | 0.00% | 0.0% |
| Q2 2017 | $16,113,000 | – | 2,192,224 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 11,826,299 | $130,562,000 | 4.09% |
| MPM BioImpact LLC | 1,200,000 | $13,248,000 | 3.68% |
| Finepoint Capital LP | 960,200 | $10,601,000 | 3.66% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 3,011 | $273,000,000 | 2.85% |
| Avoro Capital Advisors LLC | 9,220,000 | $101,789,000 | 2.01% |
| Long Focus Capital Management, LLC | 1,625,000 | $17,940,000 | 1.88% |
| 683 Capital Management, LLC | 2,000,000 | $22,080,000 | 1.56% |
| Parametrica Management Ltd | 115,870 | $1,268,000 | 1.38% |
| Boxer Capital, LLC | 1,935,133 | $21,364,000 | 1.35% |
| Soleus Capital Management, L.P. | 719,600 | $7,944,000 | 1.24% |